Kazakhstan Medical Device Registration Certificate Suspension and Revocation: Triggers and Remedies

1. Key takeaways

Medical device registration certificates in Kazakhstan have no validity period limit (Order No. 146, November 18, 2025), but this does not mean the certificate is untouchable. A registration certificate can be suspended or revoked on grounds of safety, quality and effectiveness. There are three sources of triggers: post-market surveillance (adverse events and surveillance conclusions under Order No. ҚР ДСМ-320/2020), manufacturing inspections (nonconformities found under Decision No. 106, especially where the causes leading to nonconforming devices leaving the factory have not been eliminated), and market sampling (failed retesting under Order No. ҚР ДСМ-323/2020). The remedy path is: rectification, then submission of rectification evidence, then confirmation through an unplanned inspection, then application for restoration. Each step has its own evidence requirements, and the sequence should not be shortened, because a restoration request without confirmed rectification will simply be returned.

2. Legal basis

3. Expert insights

Insight 1: the absence of an expiry date governs the time dimension; suspension and revocation govern the quality dimension. Order No. 146 answers the question of whether the certificate will expire; suspension and revocation answer the question of whether the certificate can cease to be effective. These are institutions on different dimensions, and the former must not be allowed to obscure the latter. GRZAN treats this distinction as the first lesson in client education, because certificates without an expiry date are often mistaken for certificates without regulatory risk. The register entry confirms validity, but it is the post-market record that determines whether that validity survives contact with a quality problem.

Insight 2: Decision No. 106 provides an explicit remedy channel. Under that decision, a manufacturer may proactively apply for an unplanned inspection for the purpose of confirming that the causes leading to nonconforming devices leaving the factory have been eliminated. This gives companies a formal procedure for restoring a compliant status after rectification, instead of leaving them to wait passively. Using the channel deliberately and with prepared evidence shortens the path back to full market access. The application should be supported by the same rectification evidence submitted in the remedy file, so the inspection and the file tell one consistent story.

Insight 3: the difference between suspension and revocation lies in reversibility and scope. Suspension is usually temporary and reversible; once rectification is complete and confirmed, the certificate can be restored. Revocation means the registration entitlement is extinguished and a new application is required. Once an action decision has been made, the speed of the company response directly determines the magnitude of the consequences, so the first hours after notification matter more than the following weeks. A documented escalation rule that defines who is informed and within what period removes the hesitation that slows responses in practice.

Insight 4: the three trigger sources can corroborate one another. A single adverse event may simultaneously prompt a surveillance assessment, trigger an unplanned inspection, and be confirmed by a sampling retest. When all three lines run in parallel, the company needs a single unified response team rather than three lines operating independently. Split responses produce inconsistent statements, and inconsistent statements are themselves a finding in any subsequent review. The team should include regulatory, quality, supply chain and commercial representatives with a single spokesperson for external communication.

Insight 5: the register status is the external face of any action. Suspension or revocation is reflected in the entry status of the national register. Customers, purchasers and regulators can all see it, and the commercial impact is immediate. During any period of regulatory action, the company should proactively explain the situation to key customers rather than waiting for questions to arrive through the sales channel. A short factual note covering the action taken, the remedy path and the expected timeline is usually sufficient to preserve confidence.

4. Practical recommendations

1. Build a suspension and revocation risk list that brings the three trigger sources into routine monitoring.
2. When a trigger situation appears, activate a unified response team immediately and avoid three parallel lines working in isolation.
3. Advance the remedy through four steps: rectification, submission of evidence, confirmation by unplanned inspection, application for restoration.
4. Use the unplanned inspection channel of Decision No. 106 to confirm rectification results proactively.
5. During any regulatory action, communicate proactively with key customers and purchasers to manage the commercial impact.

5. Verification checklist

• □ A suspension and revocation risk list has been built, with the three trigger sources under routine monitoring
• □ A unified response team mechanism has been established (surveillance, inspection and sampling combined)
• □ The four-step remedy path is defined (rectification, evidence, inspection, restoration)
• □ The unplanned inspection channel of Decision No. 106 has been built into the rectification plan
• □ A customer communication plan for the period of regulatory action has been prepared
• □ Monitoring of register status changes has been set up so changes are known immediately

Regulatory information verified as of October 29, 2026.

GRZAN provides registration and post-market compliance support for medical device manufacturers, importers and authorized representatives in Kazakhstan, including certificate defense, rectification planning and register status monitoring. For inquiries, contact info@grzanglobal.com.